Association of Circulating Long Noncoding 7S RNA with Deep Vein Thrombosis

Abstract

Mitochondrial dysfunction is a recognized factor in the pathogenesis of deep vein thrombosis (DVT). The role of 7S RNA, a long noncoding RNA that plays an important role in mitochondrial function, in DVT remains unclear. In this study, we aimed to investigate the potential use of 7S RNA as a biomarker in DVT. Plasma samples were obtained from 237 patients (aged 16–95 years) with suspected DVT recruited in a prospective multicenter management study (SCORE) where 53 patients were objectively confirmed with a diagnosis of DVT and the rest were diagnosed as non-DVT. 7S RNA was measured using quantitative real-time polymerase chain reaction in plasma samples. The plasma expression of 7S RNA was significantly lower in DVT compared with non-DVT (0.50 vs. 0.95, p = 0.043). With the linear regression analysis, we showed that the association between the plasma expression of 7S RNA and DVT (β = −0.72, p = 0.007) was independent of potential confounders. Receiver-operating characteristic curve analysis showed the area under the curve values of 0.60 for 7S RNA. The findings of the present study showed a notable association between 7S RNA and DVT. However, further investigations are needed to fully elucidate the exact role of 7S RNA in the pathophysiology of DVT and its diagnostic value.

Keywords

long noncoding RNA - 7S RNA - venous thromboembolism - deep venous thrombosis - diagnosis

Authors' Contributions

X.W., A.A.M., J.L.E., P.J.S., J.S., and K.S. conceived and designed the study; X.W. and A.H. performed the experimental analysis; X.W. and A.G. performed the statistical analysis; J.L.E. and P.J.S. collected clinical data. X.W., A.A.M., A.G., J.S., and K.S. performed the interpretation of results; X.W. wrote the first draft and A.A.M., A.G., A.H., J.L.E., P.J.S., J.S., and K.S. revised the article and approved the last version.

Ethical Approval and Consent to Participate

The study was performed according to the principles of the Declaration of Helsinki. All the patients have given their informed written consent before enrollment in the SCORE study. These studies were approved by the Ethics Committee of Lund University, application no. 491/2015.

Publikationsverlauf

Artikel online veröffentlicht:
23. August 2023

• References

• 1 Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158 (06) 585-593
• 2 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5 (04) 692-699
• 3 Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012; 379 (9828) 1835-1846
• 4 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353 (9159) 1167-1173
• 5 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (23, Suppl 1): I4-I8
• 6 Elf JL, Strandberg K, Nilsson C, Svensson PJ. Clinical probability assessment and D-dimer determination in patients with suspected deep vein thrombosis, a prospective multicenter management study. Thromb Res 2009; 123 (04) 612-616
• 7 Ghanbari M, Franco OH, de Looper HWJ, Hofman A, Erkeland SJ, Dehghan A. Genetic variations in microRNA-binding sites affect microRNA-mediated regulation of several genes associated with cardio-metabolic phenotypes. Circ Cardiovasc Genet 2015; 8 (03) 473-486
• 8 Wang X, Sundquist K, Hedelius A, Palmér K, Memon AA, Sundquist J. Circulating microRNA-144-5p is associated with depressive disorders. Clin Epigenetics 2015; 7 (01) 69
• 9 Wang X, Sundquist K, Svensson PJ. et al. Association of recurrent venous thromboembolism and circulating microRNAs. Clin Epigenetics 2019; 11 (01) 28
• 10 Lajoie AC, Provencher S, Paulin R, Bonnet S, Potus F. Chapter 26 - MicroRNA targeted therapy in cardiovascular disease. In: Xiao J. eds. MicroRNA. Academic Press; 2022: 521-547
• 11 Çakmak HA, Demir M. MicroRNA and cardiovascular diseases. Balkan Med J 2020; 37 (02) 60-71
• 12 Sun H, Wu S, Sun B. MicroRNA-532-5p protects against atherosclerosis through inhibiting vascular smooth muscle cell proliferation and migration. Cardiovasc Diagn Ther 2020; 10 (03) 481-489
• 13 Wang X, Sundquist K, Elf JL. et al. Diagnostic potential of plasma microRNA signatures in patients with deep-vein thrombosis. Thromb Haemost 2016; 116 (02) 328-336
• 14 Schleicher M, Shepherd BR, Suarez Y. et al. Prohibitin-1 maintains the angiogenic capacity of endothelial cells by regulating mitochondrial function and senescence. J Cell Biol 2008; 180 (01) 101-112
• 15 Johannsen DL, Ravussin E. The role of mitochondria in health and disease. Curr Opin Pharmacol 2009; 9 (06) 780-786
• 16 Scheffler IE. Mitochondria make a come back. Adv Drug Deliv Rev 2001; 49 (1-2): 3-26
• 17 Hock MB, Kralli A. Transcriptional control of mitochondrial biogenesis and function. Annu Rev Physiol 2009; 71: 177-203
• 18 Boore JL. Animal mitochondrial genomes. Nucleic Acids Res 1999; 27 (08) 1767-1780
• 19 Campbell CT, Kolesar JE, Kaufman BA. Mitochondrial transcription factor A regulates mitochondrial transcription initiation, DNA packaging, and genome copy number. Biochim Biophys Acta 2012; 1819 (9–10): 921-929
• 20 Liu X, Shan G. Mitochondria encoded non-coding RNAs in cell physiology. Front Cell Dev Biol 2021; 9: 713729
• 21 Zhu X, Xie X, Das H. et al. Non-coding 7S RNA inhibits transcription via mitochondrial RNA polymerase dimerization. Cell 2022; 185 (13) 2309-2323.e24
• 22 Reyes A, Rusecka J, Tońska K, Zeviani M. RNase H1 regulates mitochondrial transcription and translation via the degradation of 7S RNA. Front Genet 2020; 10: 1393
• 23 Elf JL, Strandberg K, Svensson PJ. The diagnostic performance of APC-PCI complex determination compared to D-dimer in the diagnosis of deep vein thrombosis. J Thromb Thrombolysis 2010; 29 (04) 465-470
• 24 Wells PS, Anderson DR, Bormanis J. et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997; 350 (9094) 1795-1798
• 25 Strandberg K, Kjellberg M, Knebel R, Lilja H, Stenflo J. A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: use of a catcher antibody specific for the complexed/cleaved form of the inhibitor. Thromb Haemost 2001; 86 (02) 604-610
• 26 Badowski C, He B, Garmire LX. Blood-derived lncRNAs as biomarkers for cancer diagnosis: the good, the bad and the beauty. NPJ Precis Oncol 2022; 6 (01) 40
• 27 Jemt E, Persson Ö, Shi Y. et al. Regulation of DNA replication at the end of the mitochondrial D-loop involves the helicase TWINKLE and a conserved sequence element. Nucleic Acids Res 2015; 43 (19) 9262-9275
• 28 Yang J, Guo Q, Feng X, Liu Y, Zhou Y. Mitochondrial dysfunction in cardiovascular diseases: potential targets for treatment. Front Cell Dev Biol 2022; 10: 841523
• 29 Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol 2021; 18 (09) 666-682
• 30 Aloni Y, Attardi G. Symmetrical in vivo transcription of mitochondrial DNA in HeLa cells. Proc Natl Acad Sci U S A 1971; 68 (08) 1757-1761
• 31 Benincasa G, Costa D, Infante T, Lucchese R, Donatelli F, Napoli C. Interplay between genetics and epigenetics in modulating the risk of venous thromboembolism: a new challenge for personalized therapy. Thromb Res 2019; 177: 145-153
• 32 Shohat N, Ludwick L, Sherman MB, Fillingham Y, Parvizi J. Using machine learning to predict venous thromboembolism and major bleeding events following total joint arthroplasty. Sci Rep 2023; 13 (01) 2197
• 33 Fan G, Jin Z, Wang K. et al. Identification of four hub genes in venous thromboembolism via weighted gene coexpression network analysis. BMC Cardiovasc Disord 2021; 21 (01) 577